REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.
This important study describes a first-in-human trial of autologous p63+ stem cells in patients with idiopathic pulmonary fibrosis, a lethal condition for which effective treatments are lacking. The ...
A 32-year-old Australian woman’s life took an unexpected turn after a seemingly harmless pimple on her forehead turned out to be a sign of skin cancer. Rachel Olivia initially dismissed the small red ...